Wh Why are y are we he e here? re? Lead smart watch technology - PowerPoint PPT Presentation

Wh Why are y are we he e here? re? Lead smart watch technology for LO LONG NG TERM TERM, CONTINUOUS, COMFORTABLE monitoring of life-critical functions at MEDICALLY CERTIFIED SENSITIVITY AND SPECIFICITY LEVELS , in order to track: VITAL WELL-BEING HEART SIGNS METRICS CONDITIONS Arrhythmia Blood Pressure Activity Tracking Atrial Fibrillation Skin Temperature Calories Burned Bradycardia Pulse Rate Galvanic Skin Response Tachycardia Respiratory Rate Mental Stress Cardiac Arrest Oxygen Saturation Sleep Analysis Heart Failure Blood Glucose Broad Health & Wellness Longer term: provide wrist-based hospital-grade diagnostics anywhere

Do we we ne need d an anoth ther r sm smar artw twatc atch h or medica ical l we wear arab able? le?

Long-term Do we we ne need d an anoth ther r sm smar artw twatc atch h High reliability measurement & accuracy in motion or medica ical l we wear arab able? le? Comfortable and hassle-free Continuous measurement 7/24 FDA/CE clearance for medical diagnostics

Long-term High reliability measurement & accuracy in motion Comfortable We need We need anot anothe her r and hassle-free Continuous sma mart rtwa watch! tch! measurement 7/24 Long-term monitoring is the only known effective solution for heart arrhythmias FDA*/CE* clearance for medical diagnostics *In process

Ou Our val r value ue pr prop opos osit itio ion

Ou Our val r value ue pr prop opos osit itio ion • Long-term, continuous, medically certifiable measurement accuracy Breakthrough Smartwatch technology levels for heart arrhythm hmia ia as well and patent- combining state-of-the-art as vital signs in all day-to-day protected electronics, optics, mechanics conditions sensor and software algorithms to technology • Non-inflating, medically certifiable deliver a long-term, non-invasive to achieve: solution absolute blood press ssur ure measurement

Optical PPG with record accuracy, low false alarm rate and motion resistance Four Unique & Proprietary Technologies Optical PPG IP: 1 patent application

Electronics cancelling ECG & PPG artifacts noise emanating from finger movements PPG Fingers movement Four Unique & Proprietary ACCELEROMETERS Technologies Accelerometers do not sense fingers movement ECG & PPG artifact canceler Artifact sensor detects ARTIFACT movements very accurately IP: 3 patent applications

Electro-mechanical sensor for blood pressure measurement over the radial artery FDA requirements: Mean error < 5 mmHg STD = 8 mmHg mmHg = millimeters of Mercury 140 120 SYSTOLIC Four Unique & 100 Proprietary 887 measurements | Mean error = 0.33 STD = 3.0 Technologies 80 DIASTOLIC 70 60 Electro-mechanical sensor 887 measurements | Mean error = 0.22 STD = 2.1 0 200 600 400 IP: 3 patent applications

Software algorithms for precise vitals measurement based on multi-sensors Four Unique & Proprietary Technologies Software algorithms

Pr Prod oduc uct t Ha Hard rdwa ware re Smart artwat watch ch Blood Press ssure ure clip clip

CardiacSen Sense Smart rtwatch atch Patient reports Conn nnectivity tivity Instantaneous Real- Offline Time data in case of data Ecosystem Ec tem Hospital Electronic event detection Medical Records Cloud Real-Time data Offline data Big Data & AI Analytics Cloud CardiacSense Cloud Offline data Patient Big Data & AI Analytics for early detection of critical events through Offline Offline (Full digital health applications data Disclosure) Monitoring Center Cloud CardiacSense such as Apple HealthKit and Real-Time Watch Cradle and Google Fit (Event) data

Regula lar pulse se Atrial ial Fibr brillatio illation Mark Ma rket et Op Oppo port rtuni unity ty Atria ial l Fi Fibril illati lation on (AF) F) De Detect ection ion 12 12 $ X5 $B AF increa reases ses the risk k The cost of AF- Long g term monito itori ring ng The leading ing of stroke ke by 5x and relat ated ed stroke kes is the only y known n techn hnology ology for long- stroke ke severit rity y by 5x (in the U.S.) effec fective ve solution on for term m AF F diagnos gnosis is is (in the U.S.) .) heart rt arrhyt rhythmi hmias as invasi sive ve and costly y Source for $12B: Natale, A. &, Jalife, J (Eds). (2008) Atrial Fibrillation: From Bench to , (p. 13), NJ: Humana Press

Ad Addr dres essa sable ble Ma Mark rket et Si Size ze U.S. Arrhythmia opportunity (Annual patients in millions) Atrial Fibrilla rillation tion (AF) ) Detec ection tion General Population DETECTION Consumer wearables High Risk Asymptomatic Risk factors: stroke, age, DIAGNOSIS hypertension, heart failure, diabetes, etc. Symptomatic Initial Diagnostics MANAGEMENT Post-AF Procedures Ongoing Management

Ad Addr dres essa sable ble Ma Mark rket et Si Size ze U.S. Arrhythmia opportunity (Annual patients in millions) Atrial Fibrilla rillation tion (AF) ) Detec ection tion General Population DETECTION Consumer wearables High Risk Asymptomatic Risk factors: stroke, age, DIAGNOSIS hypertension, heart failure, diabetes, etc. Symptomatic Initial Diagnostics MANAGEMENT Post-AF Procedures Ongoing Management

Hypertension is a cardiovascular condition that affects 75 million lion American adults Frequ quen ent t monito itorin ring g is effec ectiv tive to detect 46 % 46 hypertension and receive preventative medical treatment or a prescription medication Do not have it under control 51 51 Current home blood pressure monitors are used occasion sionally ally, if at all. In addition, 20 20 % $B they are inflatable, subject to inacc ccuracies uracies due to movemen ment, position, time of day, size of blood pressure cuff, lack of calibra ibratio tion , “white coat syndrome” Pre-hypertension affects another and patient error Not aware are to be 75 million lion American adults having this condition Ma Mark rket et Op Oppo port rtuni unity ty Hypertension can lead to coronary heart disease, stroke and even death. Bl Blood od Pressure ssure (BP BP) ) Me Measure surement ment It is sometimes called the ” SILENT NT KILLER ”

Pot oten enti tial al Busi sine ness ss Mo Mode dels ls Strategic tegic partne tnersh rship ip between CardiacSense and leading consumer wearables and/or medical equipment companies Sales of Sales of Cardiac diacSense ense smartwat rtwatch ches es Blood od Pressure essure clips via distributors* to medical channels (subscription model): Hospitals, Assisted Living Centres, Mobile (to watch manufacturers) Cardiac Outpatient Telemetry (MOCT) centers (e.g. CardioNet, Preventice Solutions ) *Distributors provide services of marketing, sales, logistics, regulatory, and legal. Manufacturing is outsourced to medically-certified partners

Co Comp mpet etitio ition CardiacSense SENSITIVITY / Atria ial l Fi Fibril illati lation on (AF) F) De Detect ection ion SPECIFICITY (DAY-TO-DAY CONDITIONS) 80-100 60-80 iRhythm Zio Holter 40-60 Apple 4 20-40 Alivecor Fibricheck MONITORING Medtronic DURATION STILL ONLY Reveal Linq CONDITION SPOT CHECK SPOT CHECK < 2WEEKS < 1 MONTH < 3 YEARS EVERY 2 HRS. CONTINUOUS

Co Comp mpet etition ition Blo lood od Pressu ssure re (BP) P) Measur suremen ment CardiacSense BP clip HealthSTATS Bpro Omron HeartGuide Microlife wrist W100 Continuous Once every 15 min Spot-check Spot-check Monitoring duration as long as in a specific position for a full day 30-50 measurements 200 measurements + - +++ ++ Comfort Inflating cuff Inflating cuff Non-inflating Non-inflating level inside a watch over the wrist Heart arrhythmias, Integration with Heart rate Heart rate -------- other functionalities breathing rate Unit $80 $ 198 $500 $100 price